Product Overview
MVASI Bevacizumab-awwb Syringes
MVASI™ Bevacizumab-awwb, which was approved by the FDA in 2017, is now available in the United States. It is a new biosimilar to Avastin® that is widely used off-label in ophthalmology. Compliance and convenience are now possible with Edge Pharma's unit dose MVASI™ Bevacizumab-awwb syringes.
Rate and Review Edge Pharma - MVASI Bevacizumab-awwb Syringes
No reviews yet. Be the first to share your experience.
Help others choose confidently by sharing your feedback.
MVASI Bevacizumab-awwb Syringes
